Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The potential use of scyllo-inositol in treating neuropsychiatric symptoms in Alzheimer’s disease and bipolar disorder

EF 2014-15

Résumé
scyllo-Inositol is a potential drug for the treatment of Alzheimer's diseases and bipolar disorder. Both conditions currently have no cure. There is an estimated 35 million people worldwide living with Alzheimer's disease and this number is expected to increase as our population ages. Alzheimer's disease leads to dementia with neuropsychiatric symptoms, which makes it a difficult condition to live with. Caring for the patients is straining on their families and the healthcare system. Clinical trials have shown human oral intake of scyllo-inositol at the required dose to be safe. The trial also showed reduced neuropsychiatric symptoms for individuals with mild Alzheimer's disease. This project sets out to understand the effect of scyllo-inositol treatment on the myo-inositol signaling pathway. This pathway is also targeted by drugs currently used to treat bipolar disorder, a chronic neuropsychological disorder affecting more than 3 percent of the population. scyllo-Inositol treatment will be compared to drugs currently used to treat neuropsychiatric symptoms and that function in part by lowing myo-inositol levels to observe beneficial downstream effects. Drugs presently on the market for neuropsychiatric symptoms have side-effect profiles that remain a concern for chronic treatment, sedate patients such that quality of life is diminished and subpopulations of patients fail to respond to treatment. Understanding the effect and mechanism of scyllo-inositol in cells will not only help future development of scyllo-inositol into a drug for multiple conditions, but also offer further insight into Alzheimer's disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331294
Name
Hu Qingda
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The potential use of scyllo-inositol in treating neuropsychiatric symptoms in Alzheimer’s disease and bipolar disorder
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Bipolar Disorder; Calcium; Depression; Lithium; Mania; Myo-Inositol; Neuropsychiatric Symptoms; Pkc; Scyllo-Inositol
Abstract
scyllo-Inositol is a potential drug for the treatment of Alzheimer's diseases and bipolar disorder. Both conditions currently have no cure. There is an estimated 35 million people worldwide living with Alzheimer's disease and this number is expected to increase as our population ages. Alzheimer's disease leads to dementia with neuropsychiatric symptoms, which makes it a difficult condition to live with. Caring for the patients is straining on their families and the healthcare system. Clinical trials have shown human oral intake of scyllo-inositol at the required dose to be safe. The trial also showed reduced neuropsychiatric symptoms for individuals with mild Alzheimer's disease. This project sets out to understand the effect of scyllo-inositol treatment on the myo-inositol signaling pathway. This pathway is also targeted by drugs currently used to treat bipolar disorder, a chronic neuropsychological disorder affecting more than 3 percent of the population. scyllo-Inositol treatment will be compared to drugs currently used to treat neuropsychiatric symptoms and that function in part by lowing myo-inositol levels to observe beneficial downstream effects. Drugs presently on the market for neuropsychiatric symptoms have side-effect profiles that remain a concern for chronic treatment, sedate patients such that quality of life is diminished and subpopulations of patients fail to respond to treatment. Understanding the effect and mechanism of scyllo-inositol in cells will not only help future development of scyllo-inositol into a drug for multiple conditions, but also offer further insight into Alzheimer's disease.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hu, Qingda
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~